View Clinical Trial (Medical Research Study)

Relative Bioavailability of Prasugrel Orally Disintegrating Tablet Formulations and the Effect of Food on the Bioavailability of the Orally Disintegrating Tablet in Healthy Subjects

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials

---

Conditions:		Healthy Volunteers
Purpose:		The purpose of this study is to evaluate the amount of drug available in the body when given to healthy participants as two different formulations with or without a meal. In addition, this study will evaluate how much of the drug gets into the blood stream and how long the body takes to get rid of it. Information about any side effects that may occur will also be collected. Each participant will receive a total of five different treatments. Each treatment is given by mouth, once a day. The treatment period lasts for five consecutive days.
Study Summary:		The reference formulation is an orally disintegrating tablet without Magnasweet® (ODT1) and the test formulation is an orally disintegrating tablet containing Magnasweet® (ODT2).
Criteria:		Inclusion Criteria: - Body mass index (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m^2) Exclusion Criteria: - No known allergies to Prasugrel or related compound - No regular alcohol intake greater than 21 units per week for males or 14 units per week for females
NCT ID:		NCT01648790
Primary Contact:		Study Director Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Backup Contact:		N/A
Location Contact:		Dallas, Texas United States There is no listed contact information for this specific location. Site Status: N/A

---

---